This is partially true but for many things the price is different. In the US drugs are priced assuming that there are some number of rich people who can afford them. This often results in higher margin pricing which is more profitable even if the volume is lower and puts them out of reach of many. In countries with public health care, setting the price that high will typically result in near-zero sales, so the price gets set closet to the cost-benefit point to make profit in lower margins but higher volumes.
It doesn't always work like this. Some drugs are just too expensive to manufacture and the minimum profitable price is too high for the benefit in public health care. But often the bargaining and purchasing power of a public health care system can achieve lower prices for drugs and other tools.
It doesn't always work like this. Some drugs are just too expensive to manufacture and the minimum profitable price is too high for the benefit in public health care. But often the bargaining and purchasing power of a public health care system can achieve lower prices for drugs and other tools.